Dauntless cuts Kazia ADS stake to 0.0% in 13G/A

Kazia Therapeutics Ltd received an amended Schedule 13G filing from Dauntless Investment Group, LLC covering its holdings of Kazia American Depositary Shares.

Rhea-AI Filing Summary

Kazia Therapeutics Ltd received an amended Schedule 13G filing from Dauntless Investment Group, LLC covering its holdings of Kazia American Depositary Shares. As of the event date of 12/31/2025, Dauntless reports beneficial ownership of 1 American Depositary Share, representing 0.0% of the class.

Dauntless reports no sole or shared voting power over any shares and sole dispositive power over 1 share. The filer identifies itself as a single family office/passive investor and certifies that the securities are not held for the purpose of changing or influencing control of Kazia.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Kazia Therapeutics (KZIA) disclose in this Schedule 13G/A?

The filing shows Dauntless Investment Group, LLC now beneficially owns 1 Kazia American Depositary Share, representing 0.0% of the class. It updates institutional ownership records and confirms Dauntless as a passive investor with minimal economic interest.

Who is the reporting person in Kazia Therapeutics (KZIA) Schedule 13G/A Amendment No. 3?

The reporting person is Dauntless Investment Group, LLC, a Delaware entity operating as a single family office/passive investor. Its principal office is at 3283 Foxfire Dr., Milford, MI 48380, and it reports beneficial ownership over only 1 Kazia ADS.

How many Kazia Therapeutics (KZIA) shares does Dauntless report owning?

Dauntless Investment Group, LLC reports beneficial ownership of 1 Kazia American Depositary Share. This position represents 0.0% of the outstanding class, indicating a negligible stake and no meaningful voting or economic influence on the company.

Does Dauntless have voting power over its Kazia Therapeutics (KZIA) shares?

Dauntless reports no sole or shared voting power over Kazia ADS. It has sole dispositive power over 1 share, meaning it can decide how to dispose of that share but does not control how any shares are voted.

Is Dauntless Investment Group acting as a passive or activist holder in Kazia Therapeutics (KZIA)?

Dauntless identifies itself as a single family office/passive investor and certifies the Kazia securities were not acquired or held to change or influence control. The position is reported under Schedule 13G, which is used for passive beneficial ownership.

What ownership threshold does this Kazia Therapeutics (KZIA) filing indicate for Dauntless?

The filing states Dauntless’ beneficial ownership is 5 percent or less of the Kazia ADS class, with a calculated percentage of 0.0%. This confirms it is far below major shareholder thresholds typically associated with significant influence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:15 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

KAZIA THERAPEUTICS LTD

(Name of Issuer)

American Depository Shares

(Title of Class of Securities)

48669G105

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 48669G105

1

Names of Reporting Persons

Dauntless Investment Group, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Single Family Office/Passive Investor

SCHEDULE 13G

Item 1.
(a)	Name of issuer: KAZIA THERAPEUTICS LTD
(b)	Address of issuer's principal executive offices: Three International Towers, Level 24, 300 Barangaroo Avenue, SYDNEY NSW, AUSTRALIA, 2000.
Item 2.
(a)	Name of person filing: Dauntless Investment Group, LLC
(b)	Address or principal business office or, if none, residence: 3283 Foxfire Dr., Milford, MI 48380
(c)	Citizenship: Delaware
(d)	Title of class of securities: American Depository Shares
(e)	CUSIP No.: 48669G105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1
(b)	Percent of class: 0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dauntless Investment Group, LLC

Signature:	/s/Matthew Okkerse
Name/Title:	CFO
Date:	02/12/2026